MUC16 and neoplasm: Moreover, when TR3 and Meso64-TR3 were tested in a preclinical model of MUC16-positive ovarian cancer, the targeted drug variant outperformed its non-targeted analog with regard to a delay in tumor growth (Figure 2D), which corresponded with a significant life extension of the animals, with median survivals of 23.5 days (control), 26.5 days (TR3) and 32.5 days (Meso64-TR3), respectively (Figure 2E).